Salix Pharmaceuticals and Cosmo Pharmaceuticals have called off their $2.7 billion merger, citing recent moves by the U.S. Treasury Department to make it more difficult for companies to complete ...

After four years working to turn around Bausch Health's Salix Pharmaceuticals, President Mark McKenna is leaving. McKenna will this week become the CEO of a new precision medicine drug developer, ...

Health care mergers and acquisitions is alive and well as confirmed by Valeant Pharmaceuticals (VRX) acquisition of Salix Pharmaceuticals (SLXP) announced over the weekend. Canada-based Valeant, a ...

RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will host a DDW2010 Investor Event on Monday, May 3 2010 from 9:00 p.m. to 10:00 p.m.

Salix Pharmaceuticals and Cosmo Pharmaceuticals have agreed to a merger in which Salix will become a subsidiary of an Irish-domiciled unit of Cosmo that will change its name to Salix. That will enable ...

For starters, in February, Valeant announced that it would be forced to restate its fiscal 2014 and 2015 earnings, delaying its annual report for 2015, after it uncovered $58 million in improperly ...

RALEIGH, N.C. & LAINATE, Italy, Oct 03, 2014 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. ("Salix") SLXP, +5.37% and Cosmo Pharmaceuticals S.p.A. ("Cosmo") (six:COPN) today announced that they have ...

Salix Pharmaceuticals roars higher after delivering positive late-stage results that could expand the prescribed indications for one of its lead drugs. Find out if this move higher is merited.